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Abstract
Objective Immunodeficiency of end-stage renal disease
(ESRD) is caused by several factors including uremic
toxins and biocompatibility reactions due to the repeated
hemodialysis (HD) procedure. It has also been suggested
that poor T cell responses could be associated with the
increased number of regulatory T cells (Tregs) which are
necessary to limit the function of activated T cells. The aim
of the study was to determine the proportion of
CD4?CD25? cells (activated T cells) to CD4lowCD25high
cells (Tregs) within the CD4? population in ESRD
patients.
Patients and methods Two groups of ESRD patients,
predialysis patients treated conservatively and patients
undergoing hemodialysis (HD), as well as healthy controls
were included in the study. Percentages of activated and
regulatory T cells were determined ex vivo with flow
cytometry based on the expression of CD4 and CD25
antigens.
Results and conclusions HD patients showed an
increased percentage of CD4?CD25? cells when compared
with healthy controls, while there was no difference in the
percentage of CD4lowCD25high cells between the patient
groups. In our opinion, the repeated hemodialysis proce-
dure significantly disturbs the balance between activated T
cells and regulatory T cells in ESRD patients. Lack of Treg
mobilization and chronic stimulation of T cells may con-
tribute to the immune deficiency observed in these patients.
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Introduction
Despite developments in end-stage renal disease (ESRD)
therapy, nearly half of hemodialysis (HD) patients suffer
from chronic inflammation which is caused by several
factors including uremic toxins and biocompatibility
reactions [1]. It causes a chronic stimulation of lympho-
cytes which results in immunodeficiency manifested by
susceptibility to infections (reviewed in [2]) and poor
response to vaccination [3]. In vitro, CD4? T cells of HD
patients present decreased proliferative capacity as well as
decreased interleukin 2 (IL-2) and interferon gamma (IFN-
c) production in response to stimulation [4–6]. However, it
has also been suggested that poor T cell responses could be
associated with the increased number or inappropriate
function of regulatory T cells (Tregs) which are necessary
to limit the function of activated T cells. Tregs as the
master regulators of immune response act either by secre-
ted cytokines or cell-to-cell interactions with effector T
cells (reviewed in [7]). There is still little known about the
role of Tregs in the development of immunodeficiency in
ESRD. Moreover, contrasting results have been reported.
Hendrikx et al. [8] observed a lower number and an
impaired function of CD4?CD25high regulatory T cells. In
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response to the article of Hendrikx et al., Libetta et al. [9]
reported a significantly higher number and percentage of
CD4?CD25high cells in HD patients. According to Meier
et al. [10], high levels of low-density lipoproteins in HD
patients reduces the number of Tregs and interferes with
their function.
Identification of regulatory T cells is still problematic,
especially after discovering that transcription factor FoxP3
(forkhead box P3), currently the most reliable marker for
Tregs, is also induced upon activation of CD4? T cells
[11]. According to Bryl et al. [12], significantly low
expression of CD4 simultaneous with high expression of
CD25 is a sufficient marker of functional human Tregs.
Cells with this phenotype express perforin and granzyme B
which allows them to kill effector cells directly [12].
Therefore, we used this phenotypic criterion to analyze
proportions of CD4?CD25- cells (naive T cells),
CD4?CD25? cells (activated T cells) and CD4lowCD25high
cells (Tregs) within populations of CD4? cells in ESRD
patients, those not yet treated with dialysis (predialysis,




The inclusion criteria for patients was the fifth stage of
chronic kidney disease (CKD). The study group consisted
of 19 ESRD patients and 10 healthy volunteers. Nine of the
patients were undergoing 5-h sessions of hemodialysis
three times a week (the average length of time on he-
modialysis was 13.83 ± 20.32 months). The remaining ten
patients were being treated conservatively (predialysis,
PD). The exclusion criteria for patients and healthy vol-
unteers included infections, inflammation, malnutrition,
neoplasm and blood loss during the study. None of the
patients received erythropoiesis stimulating agents (ESA).
The study was approved by the Ethical Committee of the
Medical University of Gdan´sk.
Flow cytometry
Five milliliters of venous peripheral blood from patients
and healthy volunteers was collected in EDTA-coated
tubes. Samples of 50 ll blood per tube were transferred for
staining with monoclonal antibodies and red blood cell
(RBC) lysis as previously described [4]. Blood cells were
incubated with fluorescein isothiocyanate (FITC)-conju-
gated anti-CD3, R-phycoerythrin (RPE)-Cy5-conjugated
anti-CD4 (DAKO, Denmark) and PE-conjugated anti-
CD25 (BD-Pharmigen, USA) for 30 min at 4 C and
analyzed on FACScan (Becton–Dickinson, USA).
Statistical analysis
T cells were selected on the basis of their forward and side
scatter characteristic and CD3 expression with Cyflogic,
version 1.2.1 (Perttu Terho and CyFlow Ltd). T regu-
latory cells were identified based on their low CD4
expression simultaneous with high CD25 expression
(Fig. 1a) as described by Bryl et al. [12]. In order to dis-
tinguish CD4lowCD25high (regulatory T cells) from
CD4?CD25? cells (activated T cells), we applied the
rhomboid regions to avoid overlapping of the lowest CD25
signal level shown by the CD4low population and the
highest one shown by other CD4? cells [12].
Statistical analysis was performed using the Statistica,
version 8 (StatSoft, Poland). The significance tests were
chosen according to data distribution with the level of
significance p B 0.05.
Results
The main clinical and immunological features of patients
and controls are presented in Table 1. All groups were
similar regarding age and gender. Creatinine was signifi-
cantly increased while hemoglobin and RBC were
significantly decreased in PD and HD patients when
compared with healthy controls. The percentage of lym-
phocytes was also significantly decreased in PD patients
when compared with healthy controls. The percentage and
absolute number of CD4? cells did not differ between the
groups. There was also no difference in the number of
CD4? subpopulations with a different expression of CD25
antigen (Table 1).
Figure 1 shows the proportion of CD4?CD25-,
CD4?CD25? and CD4lowCD25high cells within the CD4?
population in ESRD patients and healthy controls. The
percentage of CD4?CD25- cells in HD patients was sig-
nificantly decreased compared with healthy controls
(Fig. 1b) while the percentage of CD4?CD25? cells was
significantly increased (Fig. 1c). No difference was seen in
the percentage of CD4lowCD25high cells in the examined
groups (Fig. 1d). There was an increase in the ratio of
CD4?CD25? to CD4lowCD25high in HD patients (Fig. 1e).
Discussion
The balance between activated T cells and Tregs is crucial
for immune homeostasis. This process involves activation
of T cells followed by the expansion of Tregs in order to
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limit the function of activated T cells. It has been suggested
that deficient responses of T cells in ESRD patients could
be partly associated with the increased number of circu-
lating Treg cells. However, articles on Tregs present
conflicting results when it comes to the proportions of
CD4?CD25high regulatory T cells in these patients [8–10,
13].
The immune system of ESRD patients is affected by
many factors including uremic toxins, bacterial products,
repeated infections and biocompatibility reactions [1]. As a
result, there is an activation of T cells seen as disturbances
in subpopulations of cells ex vivo; HD patients are char-
acterized by a reduced percentage of CD4? cells with
CD69 antigen, an early marker of activation, and an
increased percentage of cells with late activation markers,
like CD95 and HLA-DR [14]. The consequence of pre-
mature activation of T cells is their impaired proliferative
capacity and decreased cytokine production [4–6, 14]. Our
current results show an imbalance between CD4?CD25?
(activated T cells) and CD4lowCD25high (Tregs) in HD
patients which is the result of an increase in the percentage
of the former. This demonstrates the absence of regulatory
T cell mobilization despite the presence of T cell activation
in these patients. Recently Afzali et al. [13] also showed
that there is no difference in the percentage and absolute
number of CD4lowCD25high cells between HD patients and
healthy controls which is consistent with our results.
However, Afzali et al. reported that Tregs of HD patients
Fig. 1 Comparison of activated
and regulatory T cells within the
CD4? population ex vivo. T
regulatory cells were identified
based on low expression of CD4
simultaneous with high
expression of CD25 (a) as




CD4lowCD25high cells (d), and
CD4?CD25?/CD4lowCD25high
ratio (e) in predialysis (PD) and
hemodialyzed (HD) patients and
healthy controls. Midpoints of
figures represent medians, boxes
represent 25–75 % and whiskers
outside represent the minimum
and maximum of all the data,
Kruskal–Wallis and post hoc
test, p \ 0.05
CD4lowCD25high regulatory T cells in end-stage renal disease patients 101
123
were less suppressive and produced IL-17. Insufficient
Treg activity is important in the context of transplanta-
tion; however, rapamycin-based protocols to induce
tolerance to renal allografts could provide a solution to
this problem since in vitro studies have shown that rap-
amycin promotes expansion of Tregs [13, 15]. Libetta
et al. [9], who reported significantly larger numbers of
CD4?CD25high cells in HD patients, suggested that the
use of different membranes could play a role in Treg
mobilization; a low biocompatibility membrane would
activate regulatory T cells.
Variations in reports on the percentage or the number of
circulating regulatory T cells probably result from the use
of different Treg markers and different methods of ana-
lysis. It is also worth noting that researchers rarely examine
the ratio of activated to regulatory T cells, which is a useful
factor in evaluating whether there is a balance between
these cells. Our results show that the proportions of acti-
vated and regulatory T cells may be affected in the various
groups studied, despite the lack of differences in the
number of cells of a given population. Nevertheless, it
appears that hemodialysis not only contributes to the
excessive activation of T cells, but also interferes with the
mobilization of Tregs, thereby disturbing the balance
between these cells in ESRD patients.
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